Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KROS Keros Therapeutics, Inc.

Market Closed 01-09 16:00:00 EST

19.20

+0.62

+3.34%

盘后19.20

+0.000.00%

19:58 EST

High19.49	Low18.72	Vol459.11K
Open18.87	D1 Closing18.58	Amplitude4.14%
Mkt Cap584.95M	Tradable Cap433.00M	Total Shares30.47M
T/O8.81M	T/O Rate2.04%	Tradable Shares22.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KROS","market":"US","secType":"STK","nameCN":"Keros Therapeutics, Inc.","latestPrice":19.2,"timestamp":1767992400000,"preClose":18.58,"halted":0,"volume":459113,"hourTrading":{"tag":"盘后","latestPrice":19.2,"preClose":19.2,"latestTime":"19:58 EST","volume":5358,"amount":102872.75,"timestamp":1768006700740},"delay":0,"floatShares":22552100,"shares":30466069,"eps":1.574699,"marketStatus":"Market Closed","change":0.62,"latestTime":"01-09 16:00:00 EST","open":18.87,"high":19.49,"low":18.72,"amount":8808699.034646,"amplitude":0.041442,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.574699,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"listingDate":1586318400000,"exchange":"NASDAQ","adjPreClose":18.58,"preHourTrading":{"tag":"盘前","latestPrice":19.04,"preClose":18.58,"latestTime":"09:20 EST","volume":704,"amount":13341.340672,"timestamp":1767968400779},"postHourTrading":{"tag":"盘后","latestPrice":19.2,"preClose":19.2,"latestTime":"19:58 EST","volume":5358,"amount":102872.75,"timestamp":1768006700740},"volumeRatio":0.8986948447850979,"impliedVol":0.5894,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/KROS","defaultTab":"news","newsList":[{"id":"2602304806","title":"Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304806","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304806?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:51","pubTimestamp":1767995513,"startTime":"0","endTime":"0","summary":"An update from Keros Therapeutics ( ($KROS) ) is now available. On January 9, 2026, Keros Therapeutics updated its corporate presentation for inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-highlights-rinvatercept-strategy-in-updated-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-highlights-rinvatercept-strategy-in-updated-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539","KROS"],"gpt_icon":0},{"id":"2589733402","title":"Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2589733402","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589733402?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:18","pubTimestamp":1765189088,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) has suddenly jumped about 30% over the past month, drawing fresh attention just as Wall Street is bracing for roughly 40% annual revenue contraction over the next few years.\nSee our latest analysis for Keros Therapeutics.\nThe latest burst of buying has pushed Keros Therapeutics’ share price to 21.69, with a 30 day share price return of roughly 34% and a 90 day gain near 38%. However, the 1 year total shareholder return is still deep in negative territory. This...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kros/keros-therapeutics/news/keros-therapeutics-kros-valuation-check-after-sharp-share-pr","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kros/keros-therapeutics/news/keros-therapeutics-kros-valuation-check-after-sharp-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KROS"],"gpt_icon":0},{"id":"2585168317","title":"BRIEF-Keros Therapeutics Announces Final Results Of Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168317","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168317?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:38","pubTimestamp":1763674718,"startTime":"0","endTime":"0","summary":"BRIEF-Keros Therapeutics Announces Final Results Of Tender OfferKeros Therapeutics Inc KROS.O:KEROS THERAPEUTICS ANNOUNCES FINAL RESULTS OF TENDER OFFERSource text: ID:nGNXw8jwYFurther company coverage: KROS.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6KXDVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2584094980","title":"Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584094980","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584094980?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:47","pubTimestamp":1763556445,"startTime":"0","endTime":"0","summary":"Keros Therapeutics  said Wednesday that it will repurchase almost 11 million shares at $17.75 each, or a total of $194.4 million, in a tender offer that expired on Tuesday.The offer was oversubscribed, with about 16.7 million shares validly tendered and about 1.2 million shares tendered through notice of guaranteed delivery, the company said.The shares to be acquired represent around 35.91% of the company's outstanding stock as of Tuesday, Keros said","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2584910090","title":"Keros Therapeutics Inc - Announces Tender Offer to Repurchase Common Shares for $194.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910090?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA37LNL5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2582368374","title":"Keros Therapeutics Inc. : Oppenheimer Raises Target Price to $27 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368374?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:34","pubTimestamp":1762954483,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nAZN4QQN0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2581704510","title":"Biopharma company Keros' Q3 net loss narrows on Takeda license revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2581704510","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581704510?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:12","pubTimestamp":1762377153,"startTime":"0","endTime":"0","summary":"Biopharma company Keros' Q3 net loss narrows on Takeda license revenueOverviewKeros Q3 net loss narrows to $7.3 mln from $53 mln, largely due to Takeda license revenueCompany plans to return $375 mln ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2581709940","title":"Keros Therapeutics reports third quarter net loss of $7.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709940?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:03","pubTimestamp":1762376597,"startTime":"0","endTime":"0","summary":"Keros Therapeutics reported a net loss of $7.3 million for the third quarter of 2025, compared to a net loss of $53.0 million for the same period in 2024. The decrease in net loss was primarily due to revenue recognized from Keros' license agreement with Takeda Pharmaceuticals, partially offset by ongoing research and development expenses and corporate investments. Research and development expenses decreased to $19.5 million from $49.2 million, mainly due to the transition of elritercept-related costs to Takeda. General and administrative expenses were $10.1 million, slightly up from $9.8 million, reflecting increased external expenses and a reduction in compensation costs following a headcount reduction. Cash and cash equivalents were $693.5 million as of September 30, 2025, up from $559.9 million at the end of 2024. Keros expects its cash reserves, after returning $375.0 million to shareholders, to fund operations into the first half of 2028. Key business developments include Takeda'","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL5vNX1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2580541030","title":"Keros Therapeutics Inc  expected to post a loss of $1.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580541030","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580541030?lang=en_us&edition=fundamental","pubTime":"2025-11-01 07:35","pubTimestamp":1761953708,"startTime":"0","endTime":"0","summary":"Keros Therapeutics Inc  expected to post a loss of $1.05 a share - Earnings Preview Keros Therapeutics Inc KROS.OQ KROS.O is expected to  show a rise in quarterly revenue when it reports  results on N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC2NO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"1104598229","title":"Keros Initiates Share Repurchase Program of Up to $194.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1104598229","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104598229?lang=en_us&edition=fundamental","pubTime":"2025-10-20 22:00","pubTimestamp":1760968852,"startTime":"0","endTime":"0","summary":"In early trading on Monday, shares of clinical-stage drug developer Keros Therapeutics, Inc. (KROS) rose by 2.1%, following the announcement of its plan to repurchase up to $194.4 million of its own...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2576588358","title":"Keros Therapeutics to repurchase $194.4M of shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576588358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576588358?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:11","pubTimestamp":1760955072,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has commenced a cash tender offer to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-to-repurchase-194-4m-of-shares-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-to-repurchase-194-4m-of-shares-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KROS","BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2576683778","title":"Keros Therapeutics Inc - Expects to Fund Tender Offer From Its Existing Cash and Cash Equivalents","url":"https://stock-news.laohu8.com/highlight/detail?id=2576683778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576683778?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:00","pubTimestamp":1760954406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0EJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2576062468","title":"Pontifax Management 4 G.P. (2015) Ltd. Reports Disposal of Keros Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576062468","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576062468?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:54","pubTimestamp":1760738053,"startTime":"0","endTime":"0","summary":"Pontifax Management 4 G.P.  Ltd. and other reporting beneficial owners have reported the disposal of common shares of Keros Therapeutics Inc, according to a recent SEC Form 4 filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL6ybVXr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2575828762","title":"Major Shareholder Sells Millions in Keros Therapeutics Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2575828762","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575828762?lang=en_us&edition=fundamental","pubTime":"2025-10-16 10:03","pubTimestamp":1760580196,"startTime":"0","endTime":"0","summary":"New insider activity at Keros Therapeutics ( ($KROS) ) has taken place on October 15, 2025. Significant shareholder ADAR1 Capital Management, LLC h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-millions-in-keros-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-millions-in-keros-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","KROS","BK4007","LENZ"],"gpt_icon":0},{"id":"2575737294","title":"ADAR1 Capital Management, LLC Reports Disposal of Common Shares of Keros Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2575737294","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575737294?lang=en_us&edition=fundamental","pubTime":"2025-10-16 01:25","pubTimestamp":1760549100,"startTime":"0","endTime":"0","summary":"ADAR1 Capital Management, LLC reported a disposal of common shares of Keros Therapeutics Inc , according to a recent SEC Form 4 filing. The form was filed by ADAR1 Capital Management, LLC, ADAR1 Partners, LP, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL1PQQ2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2575835957","title":"Keros Therapeutics Inc - Aggregate Purchase Price for Repurchase Is $181 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2575835957","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575835957?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:30","pubTimestamp":1760524207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2BH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2575783571","title":"Keros Therapeutics Inc - to Distribute 25% of Takeda Proceeds to Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2575783571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575783571?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:30","pubTimestamp":1760524207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2BH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2575651783","title":"Keros Therapeutics Inc - Intends to Commence Tender Offer for $194 Mln in Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575651783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575651783?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:30","pubTimestamp":1760524207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2BH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2575783365","title":"Press Release: Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2575783365","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575783365?lang=en_us&edition=fundamental","pubTime":"2025-10-15 18:30","pubTimestamp":1760524200,"startTime":"0","endTime":"0","summary":"Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital. Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares. \"We are pleased to have reached these agreements with ADAR1 and Pontifax, and look forward to completing our capital return program in the near term. The capital return program -- which includes an additional commitment to distribute future near-term Takeda proceeds -- reflects our confidence in the outlook for Keros and the prospects for our key clinical program, KER-065,\" said Jean-Jacques Bienaimé, Chair of the Board of Directors. \"With a more focused and streamlined organization, supported by a strong financial position, we are moving forward fully focused on the execution of our clinical strategy. We continue to target a first quarter 2026 start of the Phase 2 clinical trial of KER-065 in patients with Duchenne muscular dystrophy , subject to positive regulatory interaction, and believe Keros is well","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2565381689","title":"Keros Therapeutics Unveils Promising Phase 1 Trial Results for KER-065 at 2025 ASBMR Meeting, Highlighting Potential in Duchenne Muscular Dystrophy and Bone Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2565381689","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565381689?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:04","pubTimestamp":1757333099,"startTime":"0","endTime":"0","summary":"Keros Therapeutics Unveils Promising Phase 1 Trial Results for KER-065 at 2025 ASBMR Meeting, Highlighting Potential in Duchenne Muscular Dystrophy and Bone Disorders. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL96BsTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kerostx.com","stockEarnings":[{"period":"1week","weight":0.0356},{"period":"1month","weight":-0.1209},{"period":"3month","weight":0.2229},{"period":"6month","weight":0.3296},{"period":"1year","weight":0.2895},{"period":"ytd","weight":-0.057}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.020582},{"month":2,"riseRate":0.6,"avgChangeRate":0.081109},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068893},{"month":4,"riseRate":0.4,"avgChangeRate":0.047555},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.095298},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.056826},{"month":7,"riseRate":0.666667,"avgChangeRate":0.015981},{"month":8,"riseRate":0.5,"avgChangeRate":0.081534},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03143},{"month":10,"riseRate":0.5,"avgChangeRate":0.115174},{"month":11,"riseRate":0.666667,"avgChangeRate":0.148933},{"month":12,"riseRate":0.5,"avgChangeRate":-0.050903}],"exchange":"NASDAQ","name":"Keros Therapeutics, Inc.","nameEN":"Keros Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Keros Therapeutics, Inc.,KROS,Keros Therapeutics, Inc.股票,Keros Therapeutics, Inc.股票老虎,Keros Therapeutics, Inc.股票老虎国际,Keros Therapeutics, Inc.行情,Keros Therapeutics, Inc.股票行情,Keros Therapeutics, Inc.股价,Keros Therapeutics, Inc.股市,Keros Therapeutics, Inc.股票价格,Keros Therapeutics, Inc.股票交易,Keros Therapeutics, Inc.股票购买,Keros Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}